What is the 13F Pro Quality Score for ARWR?

13F Pro ranks ARROWHEAD PHARMACEUTICALS, INC. (ARWR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ARWR's current score at https://13fpro.ai/research/ARWR (free sign-up required for the full ranking).

Which hedge funds own the most ARWR stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ARWR include BlackRock,, Avoro Capital Advisors, FMR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ARWR as soon as new 13F filings post.

Where does 13F Pro source ARWR data?

All ARROWHEAD PHARMACEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. ARROWHEAD PHARMACEUTICALS, INC. files with the SEC under CIK 879407. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ARWR in?

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ARWR research updated on 13F Pro?

ARWR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ARROWHEAD PHARMACEUTICALS, INC.(ARWR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 879407 ARWR stock profile & AI dashboard →

13F Pro Quality Score

74.4/100

Rank #163 of 2,879 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

99.9/100

Profitability

77.4/100

Balance Sheet

77.6/100

Earnings Quality

30.0/100

Free Cash Flow

91.0/100

Institutional Flow

79.3/100

Revenue Scale

47.8/100

Dilution Risk

20.2/100

ARWR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ARROWHEAD PHARMACEUTICALS, INC. (ARWR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ARWR at 74.4/100 on a 32-signal composite quality model, placing it at rank #163 of 2,879 stocks — the top 10% of the AI-ranked universe. ARWR scores in the top quartile across revenue growth (99.9), free cash flow (91.0), institutional flow (79.3). Areas of concern include earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 20.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ARROWHEAD PHARMACEUTICALS, INC. reports quarterly revenue of $73.7M, net income of $-132.7M, free cash flow of $81.9M. Top institutional holders of ARWR by reported 13-F value include BlackRock,, Avoro Capital Advisors, FMR, based on the most recent SEC filings. ARWR trades on the Nasdaq exchange and files with the SEC under CIK 879407. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ARWR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ARROWHEAD PHARMACEUTICALS, INC. directly from SEC EDGAR. ARROWHEAD PHARMACEUTICALS, INC.'s 13F Pro composite quality score has ranged between 6 and 75 since 2021, currently 74.4 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about ARROWHEAD PHARMACEUTICALS, INC.

Quirks, history, and lore behind ARWR — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Pasadena, California · focused on RNA interference (RNAi) therapeutics.
2
The Numbers
A small-cap biotech with minimal product revenue — it runs largely on collaboration deals and milestone payments from larger pharma partners rather than drug sales.
3
The History
Founded in the early 2000s, it pivoted hard into RNAi and built a proprietary delivery platform called TRiM — designed to silence disease-causing genes before they cause trouble.
4
The Secret
Its pipeline targets brutal diseases like liver disorders, cardio-metabolic conditions, and pulmonary hypertension — all by turning off the genetic volume knob on a bad protein.
5
The Lore
It inked a major collaboration with Johnson & Johnson worth over a billion dollars in potential milestones, putting RNAi squarely on Big Pharma's shopping list.
6
The Giveaway
Its name evokes a hunter's weapon and a pointed drug delivery metaphor — this Pasadena RNAi specialist trades under a four-letter ticker starting with ARW.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$73.7M

Net Income

Q2 2026

$-132.7M

Free Cash Flow

Q2 2026

$81.9M

ROIC

Q2 2026

-23.0%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+23258.2% YoY

$829.4MFY 2025

FY21 $138.3MFY22 $243.2MFY24 $3.6MFY25 $829.4M

Net Income

+99.7% YoY

$-1.6MFY 2025

FY21 $-140.8MFY22 $-176.1MFY24 $-599.5MFY25 $-1.6M

Operating Income

+116.4% YoY

$98.3MFY 2025

FY21 $-149.0MFY22 $-178.5MFY24 $-601.1MFY25 $98.3M

EPS (Diluted)

+99.8% YoY

$-0.01FY 2025

FY21 $-1.36FY22 $-1.67FY24 $-5.00FY25 $-0.01

Total Assets

+21.5% YoY

$1.39BFY 2025

FY21 $710.1MFY22 $691.9MFY24 $1.14BFY25 $1.39B

Op. Cash Flow

+138.8% YoY

$179.6MFY 2025

FY21 $171.3MFY22 $-136.1MFY24 $-462.9MFY25 $179.6M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2018
Revenue	$829.4M +23258.2%	$3.6M -98.5%	$243.2M +75.9%	$138.3M +57.2%	$88.0M +445.1%	$16.1M
Net Income	$-1.6M +99.7%	$-599.5M -240.5%	$-176.1M -25.0%	$-140.8M -66.6%	$-84.6M -55.3%	$-54.5M
Operating Income	$98.3M +116.4%	$-601.1M -236.7%	$-178.5M -19.8%	$-149.0M -60.0%	$-93.2M -66.5%	$-55.9M
EPS (Diluted)	$-0.01 +99.8%	$-5.00 -199.4%	$-1.67 -22.8%	$-1.36 -61.9%	$-0.84 -29.2%	$-0.65
Total Assets	$1.39B +21.5%	$1.14B +64.7%	$691.9M -2.6%	$710.1M +35.9%	$522.5M +368.2%	$111.6M
Operating Cash Flow	$179.6M +138.8%	$-462.9M -240.0%	$-136.1M -179.5%	$171.3M +278.8%	$-95.8M -102.9%	$-47.2M

Get alerted when ARWR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ARROWHEAD PHARMACEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ARWR

BlackRock, Inc.
$1.1B18,161,519 sh
Avoro Capital Advisors LLC
$670.9M10,699,999 sh
FMR LLC
$455.6M7,266,652 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$448.1M7,146,136 sh
STATE STREET CORP
$407.3M6,496,130 sh
VANGUARD CAPITAL MANAGEMENT LLC
$378.2M6,032,416 sh
GEODE CAPITAL MANAGEMENT, LLC
$274.5M4,278,828 sh
FRED ALGER MANAGEMENT, LLC
$209.6M3,342,493 sh
Invesco Ltd.
$205.7M3,280,647 sh
Vestal Point Capital, LP
$142.6M2,275,000 sh

Fund	Value	Shares
BlackRock, Inc.	$1.1B	18,161,519
Avoro Capital Advisors LLC	$670.9M	10,699,999
FMR LLC	$455.6M	7,266,652
VANGUARD PORTFOLIO MANAGEMENT LLC	$448.1M	7,146,136
STATE STREET CORP	$407.3M	6,496,130
VANGUARD CAPITAL MANAGEMENT LLC	$378.2M	6,032,416
GEODE CAPITAL MANAGEMENT, LLC	$274.5M	4,278,828
FRED ALGER MANAGEMENT, LLC	$209.6M	3,342,493
Invesco Ltd.	$205.7M	3,280,647
Vestal Point Capital, LP	$142.6M	2,275,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ARWR on your watchlist

Track score changes the day ARROWHEAD PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ARWR a good stock to buy?

13F Pro's AI-powered analysis of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ARWR are available on the ARWR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ARWR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ARWR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ARROWHEAD PHARMACEUTICALS, INC.'s investment landscape.